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INTRODUCTION
Neuroleptic malignant syndrome (NMS) is a rare 
but life threatening idiosyncratic reaction related 
to the use of antipsychotic drugs characterised by 
hyperthermia, muscle rigidity, elevated creatinine 
kinase level and autonomic instability. NMS usually 
develops after an increase in dosage of neuroleptic 
medication. Treatment is primarily supportive, 
prompt withdrawal of the offending agent, and 
administration of drugs such as bromocriptine 
and dantrolene. Electroconvulsive therapy (ECT) 
has been found to be effective not only in patients 
with schizophrenia refractory to pharmacotherapy 
but also in severe or treatment resistant neurolep-
tic malignant syndrome patients. The similarity 
of clinical and physiological features between 
malignant hyperthermia (MH) and NMS poses a 
challenge to anaesthesiologists in relation to the use 
of MH triggering agents such as succinylcholine. 
Combination of rocuronium and sugammadex has 
been used successfully as an alternative to succinyl-
choline for electroconvulsive therapy in those with 
a history of NMS. 
CASE REPORT
A 46 year old gentleman, with underlying benign 
thyroid nodules and paranoid schizophrenia with 
prominent mood symptoms under regular psychi-
atric follow-up presented to our hospital with a one 
week history of fever, inability to speak, sialorrhoea, 
limb stiffness, profuse sweating, tremors and rigidity 
of bilateral upper and lower limbs. Medical records 
revealed that he had been on oral olanzapine for the 
last five years with a recent increase in dosing from 
10 mg to 20 mg.He had also been concomitantly 
started on oral fluoxetine 20 mg to replace oral 
fluvoxamine in view of worsening mood symptoms 
five days prior to hospital presentation.
Upon arrival in the Emergency Department, 
he was able to spontaneously open his eyes but 
was aphasic and diaphoretic. Standard vital sign 
monitoring devices were applied and revealed 
fever, with a temperature of 38.2, systolic BP of 
158 - 189 mmHg, diastolic blood pressure of 95 
- 100 mmHg, and tachycardia at 125 beats per 
minute. Neurological examination showed prom-
inent lip and jaw muscle twitching, tremor of both 
hands and cogwheel rigidity of bilateral shoulders, 
elbows and wrist, and areflexia consistent with 
Parkinsonism.
Laboratory investigations revealed mild leuko-
cytosis (11.2 x 109/L), a raised creatinine kinase 
(CK) levels of 906 U/L and mildly elevated levels 
of aspartate aminotransferase of 61 U/L. Other 
electrolytes were within normal range. Chest X-ray 
was normal and electrocardiographic examina-
tion showed sinus tachycardia with no ischemic 
changes. Urinalysis was positive for myoglobin. 
Conventional work up and laboratory param-
eters pointed towards a diagnosis of neuroleptic 
malignant syndrome (NMS), in accordance with 
the Levenson criteria where the patient exhib-
ited all three major signs (rigidity, raised CK and 
hyperthermia) and five minor signs (abnormal 
arterial pressure, tachycardia, diaphoresis, cogni-
tive impairment and leukocyctosis). Thus, both 
olanzapine and fluoxetine were immediately 
discontinued.
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ABSTRACT
We report a case involving a 46 year old male with schizophrenia 
who presented with fever, inability to speak, sialorrhoea, limb 
stiffness, profuse sweating, tremors and rigidity of bilateral upper and 
lower limbsfollowing an increase in dosage of his antipsychotics. A 
provisional diagnosis of neuroleptic malignant syndrome (NMS) was 
made based on the Levensen criteria. His antipsychotics were promptly 
discontinued and he was transferred to ICU for critical care support. 
We utilised lorazepam and prescribed bromocriptine and his NMS 
symptoms improved. However, in view of residual catatonic symptoms, 
decision was made to commence ECT. A combination of rocuronium 
sugammadex was used successfully in all his ECT procedures and found 
to be an excellent alternative to succinycholine in this patient.
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He was initially admitted to the general ward 
and given oxygen supplementation, hydrated with 
3 litres of normal saline per day and had his vital 
signs monitored closely. Despite the initial support-
ive management, patient continued to have spiking 
temperature and worsening limb rigidity. He was 
then referred for critical care support and trans-
ferred to the Intensive Care Unit (ICU) for stabilisa-
tion. In the ICU, he was put on oxygen therapy and 
prescribed oral lorazepam 1 mg. Oral bromocrip-
tine 2.5 mg 6 hourly was promptly initiated for the 
treatment of NMS. Dantrolene was initially consid-
ered as an alternative to bromocriptine but was not 
administered as patient showed signs of improve-
ment over a period of a few days.
Complete resolution of rigidity and normo-
thermia were seen four days after commencement 
of bromocriptine. In view of his catatonic state of 
schizophrenia with unresolving prominent mood 
symptoms, the psychiatry team decided to initiate 
electroconvulsive therapy (ECT) as an attempt to 
improve the patient’s psychotic symptoms.
In consideration of the patient’s underlying 
illness and current diagnosis, the anaesthesia team 
decided to support his ECT procedures in the major 
operating theatre and not in the remote ECT proce-
dure room located in the psychiatry ward where it 
is usually performed. After  pre-oxygenation with 
high flow 100% oxygen,  anaesthesia was induced 
with intravenous propofol (2  mg/kg) and rocu-
ronium (0.6 mg/kg) and patient was ventilated 
via laryngeal mask airway Proseal® connected 
to the anaesthetic machine. ECT stimulus was 
then applied, and produced an ensuing seizure. 
Sugammadex 200 mg (2 mg/kg) was administered 
after ECT approximately 10 minutes after the 
administration of rocuronium. Vital signs were 
measured prior to the induction of anaesthesia, 
pre-seizure, post-seizure, and every minute for 
10 min thereafter, and remained stable throughout 
the procedure. Propofol-rocuronium-sugammadex 
combinations at similar doses were used in all 
subsequent ECTs except on one occasion, where 
a Sevoflurane-rocuronium-neostigmine combina-
tion was used successfully.However,despite six ECT 
sessions, patient’s symptoms persisted and he was 
then rechallenged carefully with oral olanzapine to 
manage his symptoms. 
DISCUSSION
NMS is a rare but life threatening idiosyncratic 
reaction related to the use of antipsychotic drugs. 
It was first described by Delay and colleagues in 
1967 as ‘akinetic hypertonic syndrome’.1 Adnet et 
al. (2000) showed that the risk of developing NMS 
is between 0.07- 2.2%.The mortality rate of NMS 
is reported between 10% to 30% despite increased 
awareness associated with the use of typical anti-
psychotics drugs.2
NMS is diagnosed based on Levenson’s clinical 
criteria. The presence of all three major or two 
major and four minor manifestations indicates a 
high probability of NMS, if supported by clinical 
history.3 Based on the above manifestations, our 
patient had fulfilled the clinical criteria with history 
suggestive of NMS. 
There are two postulated theories to explain 
NMS, which are central dopamine receptor block-
ade and a skeletal muscle defect. Central dopamine 
receptor blockade contributes to the thermoregu-
latory failure seen in NMS. Serotonin stimulation 
in the hypothalamus leads to heat production and 
dopamine inhibits this process resulting in hyper-
thermia. The muscle rigidity and hypermetabolic 
state seen in NMS is a result of blockade of dopa-
mine receptors in the nigrostriatal system.4
Based on the second theory, NMS is thought to 
share a common pathophysiology with malignant 
hyperthermia (MH).This theory is based primarily 
on three features shared between the two conditions. 
These are: (i) presence of hyperthermia, rigidity and 
increased CK levels; (ii) treatment options for both 
conditions include dantrolene and (iii) presence of 
abnormal results in ‘in vitro’ contractility tests in 
both NMS and MH. Both in-vitro investigations 
of patients with NMS and MH revealed multiple 
skeletal muscle defects associated with increased 
release of calcium from sarcoplasmic reticulum.5
NMS can be fatal if untreated. The most import-
ant step in management of NMS would be to 
remove the causative agent. Supportive manage-
ment, including maintenance of adequate hydra-
tion, achieving normothermia, cardiorespiratory 
stability, control of agitation, and prevention of 
deep vein thrombosis, is vital in the management 
of NMS. In terms of pharmacotherapy, bromocrip-
tine and dantrolene sodium are the most frequently 
used medications. Bromocriptine helps to restore 
the balance of dopaminergic activity in the central 
nervous system. Meanwhile, dantrolene is a muscle 
relaxant that acts by inhibiting calcium release from 
sarcoplasmic reticulum. A case control analysis by 
Rosenberg et al (1989) demonstrated the use of 
bromocriptine together with supportive measures 
shortened the mean time to clinical response from 
6.8 to 1.03 days. In our case, the use of bromocrip-
tine was effective in improving his symptoms.6
ECT was commenced in our patient as he had 
persistent catatonia despite the resolution of the 
acute metabolic symptoms of NMS. ECT may be 
effective if psychotic symptoms are refractory to 
pharmacotherapy or psychiatric disease-associated 
catatonia cannot be excluded. It can also be used 
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as a treatment for NMS, because it supposedly 
increases circulating dopamine level in the central 
nervous system.7
A neuromuscular blocking agent (NMBA) is 
administered during ECT for the prevention of 
complications such as myalgia and bones frac-
ture. Succinylcholine is the most commonly used 
NMBA as it has a short duration of action and rapid 
recovery.8 In view of the common pathophysiology 
shared by NMS and MH, there is a likelihood of a 
patient with history of NMS to be more prone to 
develop MH.5 Despite this belief, there have been 
several case reports and reviews that demonstrate 
the safe use of succinylcholine for ECT in those 
with history of NMS.7
An alternative method of muscle relaxation 
in a patient with history of NMS is non-depolar-
ising muscle relaxants. In our case, we have used 
rocuronium and reversed with sugammadex. The 
option of 0.6 mg/kg rocuronium-16 mg/kg sugam-
madex as an alternative to succinylcholine was 
first described by Hoshi et al (2011).9 Kadoi et al 
(2011) compared the recovery times from 0.6 mg/
kg rocuronium-induced muscle relaxation after 
reversal with three different doses of sugammadex, 
with recovery from succinylcholine, and showed 
that 8 mg/kg of sugammadex produces equally 
rapid recovery from rocuronium-induced muscu-
lar relaxation compared with spontaneous recovery 
from 1 mg/kg succinylcholine in terms of induction 
time of neuromuscular effects and recovery from 
the effects.10 In our patient, we have successfully 
conducted ECT using a combination of 0.6mg/kg 
rocuronium and 2mg/kg Sugammadex.
CONCLUSION
In view of a common pathophysiology that has 
been suggested between NMS and MH, the possi-
bility of patients with a history of NMS being 
vulnerable to developing MH is an important factor 
when considering anaesthesia for ECT. Hence, we 
conclude that rocuronium-sugammadex is a safe 
and effective alternative in patients with a history 
of NMS. 
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